Posting of Annual Report & Notice of AGM

Summary by AI BETAClose X

Venture Life Group PLC has posted its Annual Report and Accounts for the period ended 31 May 2026, along with the Notice of Annual General Meeting, which will be held on 5 November 2026. These documents are available on the company's website.

Disclaimer*

Venture Life Group PLC
07 October 2026
 

7 October 2026

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Posting of Annual Report & Notice of AGM

 

Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, confirms that its Annual Report and Accounts for the period ended 31 May 2026, together with the Notice of Annual General Meeting, have been posted to shareholders. The documents are available to download from the investor section of the Company’s website www.venture-life.com.

The Company’s Annual General Meeting will be held on 5 November 2026 at 2:00pm at the offices of Simmons & Simmons, 1 Ropemaker Street, London, EC2Y 9SS.

 

For further information, please contact:

Venture Life Group PLC                                                                                                    +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)                           +44 (0) 20 7720 0500 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

 

About Venture Life (www.venture-life.com)

Venture Life is a growing pure-play consumer healthcare company focused on the specific market opportunity of Proactive Healthy Longevity. The company has a core portfolio, its Power Brands, of high growth, high margin products that promote and support consumer's goals of maintaining health and longevity. The Power Brands include Balance Activ in women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, and the FemiClear products which address a range of common women’s intimate health conditions.

 

These products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels. Venture Life has direct distribution in the UK, Ireland and the USA, supplying products directly to retailer partners and supporting these products in-market. Outside of these territories Venture Life uses international distribution partners to sell its products, with those partners being responsible for the support and distribution of the products in-market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings